By David Cassak
Ask John Simpson if he considers himself a businessman and he balks. An entrepreneur, perhaps, and definitely a physician, but...
John Simpson never set out to be a physician and still does not consider himself a businessman; yet he is a leading interventional cardiologist and has launched more than a half dozen successful device companies. Simpson takes pride in building successful teams, enabling him to delegate the engineering and business responsibilities to others, while focusing on what he does best: figuring out how to better treat the patient. He is perhaps best known for developing over-the-wire angioplasty through his first company, ACS, and has followed that with companies involved with ultrasound (CVIS), atherectomy (DVI and Fox Hollow), vascular closure (Perclose), and chronic total occlusions (LuMend). Simpson remains iconoclastic when it comes to patient care issues. So although angioplasty is where he made his name, he remains suspicious of stents and hopes through his current venture, Fox Hollow, to minimize their use.
By David Cassak
Ask John Simpson if he considers himself a businessman and he balks. An entrepreneur, perhaps, and definitely a physician, but...
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting some reimbursement prices. Commercial success remains mixed and some products have been withdrawn from the market.
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.